12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Humira adalimumab regulatory update

FDA approved a label extension for Humira adalimumab from Abbott to include the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to immunosuppressants. In...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >